Stayble Therapeutics Investor Relations Material
Latest events
CEO Sitdown with Kalqyl Q4 2023
Stayble Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Stayble Therapeutics
Access all reports
Stayble Therapeutics AB develops injectable treatment for chronic low back pain triggered by disc degeneration. Its portfolio includes StaYble, a combination of two drugs that are already approved for use in humans and administered as separate mechanisms at complementary sites of action, with the goal of achieving synergy, which is the treatment of pain through several independent but related mechanisms.
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
STABL
Country
🇸🇪 Sweden